Welcome to the Guo Lab at Vanderbilt University Medical Center (VUMC)! Our Principal Investigator, Xingyi Guo, PhD, is a tenured Associate Professor of Medicine, an NCI R37 MERIT Awardee, and a recipient of the Rawlings Directorship at Vanderbilt-Ingram Cancer Center and the Francis and William Blot Research Award. Our interdisciplinary research integrates bioinformatics, statistical genetics, genetic and molecular epidemiology, multi-omics, artificial intelligence, computational biology, digital pathology, and electronic health records (EHRs). We investigate common, rare, and structural genetic variants; single-cell and spatial omics; and H&E histopathology to advance understanding of colorectal cancer, colorectal adenoma, and inflammatory bowel disease and to develop precision prevention and intervention strategies.
Multi-ancestry GWAS and TWAS identify new risk loci and genes for inflammatory bowel disease (2026).
GLMM to detect risk TFs • sTF-TWAS • transTF-TWAS.
Openings for trainees and collaborators (see “Join”).
The Guo Lab investigates the genetic and molecular mechanisms underlying human cancers and gastrointestinal diseases, particularly colorectal cancer (CRC), colorectal adenoma, and inflammatory bowel disease (IBD). We develop and apply statistical, bioinformatics, and machine-learning/deep-learning methods to integrate large-scale GWAS, whole-genome sequencing, common and rare variants, structural variants, transcriptomics, epigenomics, proteomics, single-cell and spatial omics, hematoxylin and eosin (H&E) histopathology images, and longitudinal electronic health records (EHRs). Our work spans susceptibility gene and protein discovery, cell-type-specific regulatory mechanisms, disease progression and recurrence, multimodal AI risk prediction, and translation to therapeutic targets and drug repurposing. Our NCI-supported research includes R37CA227130 (MERIT), R01CA269589, and R01CA297582.
Discover susceptibility factors and characterize the effects of common, rare, and structural genetic variants across populations.
Integrate molecular and cellular data to prioritize susceptibility genes, proteins, and regulatory mechanisms.
Study colorectal adenoma susceptibility, recurrence, and progression to support precision cancer prevention.
Combine molecular, pathological, and clinical evidence to improve prediction and therapeutic discovery.
Selected figures illustrating recent projects and methods.









We build and maintain software for statistical analysis to improve discovery of risk genes and transcription factors.
Integrates cancer GWAS, proteomics, and EHRs to identify druggable proteins and therapeutic candidates.
Current members.
Selected publications from the Guo Lab (* corresponding author).
We welcome motivated trainees and collaborators. If you’re interested, please email a CV and a short description of your interests, preferred start date, and relevant experience.
Departments of Medicine & Biomedical Informatics
Vanderbilt University Medical Center
2525 West End Ave
Nashville, TN 37203